Tetracycline and Cumate-based coregulatory sequence

A combined Tet-On and Cumate inducible expression system with a complex response element and splicable intron sequence addresses the balance of high induced and low leakage transcriptional activity, enhancing performance in biotechnology and gene therapy applications.

JP7576806B2Active Publication Date: 2024-11-01SHENZHEN EUREKA BIOTECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022571240
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-22
Filing Date
2020-09-16
Publication Date
2024-11-01
Estimated Expiration
2040-09-16

AI Technical Summary

Technical Problem

Current inducible expression systems face challenges in balancing high transcriptional activity under inducing conditions while minimizing leakage transcriptional activity under non-inducing conditions, particularly in systems like Tet-On and Cumate systems, which often compromise maximal transcriptional activity to control leakage.

Method used

A combined inducible expression system incorporating a Tet-On system with a Cumate system, utilizing a complex response element with multiple TetO operators, a minimal promoter, and a CuO operator, along with a splicable intron sequence to enhance induced transcription and minimize leakage.

Benefits of technology

The system achieves significant improvements in induced transcriptional activity while maintaining low leakage activity, optimizing the balance between induced and non-induced states, suitable for applications in biotechnology, gene therapy, and transgenic plants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007576806000009
    Figure 0007576806000009
  • Figure 0007576806000010
    Figure 0007576806000010
  • Figure 0007576806000011
    Figure 0007576806000011
Patent Text Reader

Abstract

The present invention provides a nucleic acid sequence for controlling the transcription of a target nucleic acid fragment, the nucleic acid sequence comprising at least two copies of a TetO-operator sequence capable of binding to a transactivator rtTA controlled by tetracycline or its derivatives, one copy of a minimal promoter sequence containing a TATA box sequence, and at least one copy of a CuO-operator sequence capable of binding to a transcriptional repressor CymR controlled by cumate. The present invention also provides a vector comprising the nucleic acid sequence, a host cell, and a method for inducing expression of a target nucleic acid fragment in a host cell.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a tetracycline and Cumate-dependent nucleic acid sequence for controlling the transcription of a target nucleic acid fragment. Specifically, the present disclosure relates to a nucleic acid sequence for controlling the transcription of a target nucleic acid fragment, the nucleic acid sequence comprising at least two copies of a TetO-operator sequence (Tet operator, TetO) that binds to a reverse tetracycline controlled transactivator (rtTA), one copy of a minimal promoter sequence containing a TATA box sequence, and at least one copy of a CuO-operator sequence (Cumate operator, CuO) that binds to a CymR transcription repressor. In addition, there is further a splicable intron sequence between the downstream of the 3' end of the nucleic acid sequence and the upstream of the 5' end of the controlled target nucleic acid fragment, which can be used to further improve the transcription activity after induction without leakage without induction. In addition, the present disclosure further relates to a vector, a virus, a cell, a transgenic plant or an animal comprising the above control sequence. [Background technology]

[0002] Gene expression can be controlled by controlling several steps including transcription, RNA splicing, translation and post-translational modification, and controlling a specific gene or target nucleic acid fragment at the transcription step is the most widespread and most effective expression control method. Inducible expression systems that control the on or off of transcription and expression of specific genes and nucleic acid fragments in cells, plants or animals by exogenous elements play an important role in the fields of basic biological science research, biopharmaceuticals, gene therapy, cell therapy, transgenic plant or animal improvement, etc. Usually, the inducible expression system is designed to include two parts: 1) a part of a specific nucleic acid sequence upstream of the 5' end of the controlled target nucleic acid fragment, such as a nucleic acid sequence containing an operator, which can bind to a transcription activator or repressor to control the transcription of the target nucleic acid fragment (this nucleic acid sequence is hereinafter referred to as a response element), and 2) a single or multiple regulatory element that can bind to or separate from the specific nucleic acid sequence under the control of an external element, generally has a transcription activation or repression function, and is usually an expression protein. The external factors may be environmental factors such as temperature and light, or may be constituent substances involved in vital activities such as metabolites, hormones, metal ions, and artificial compounds.

[0003] The "Tetracycline inducible system" or "Tet System" is currently one of the most widely used inducible expression systems in scientific research and commerce. (See, e.g., Gossen, M. and H. Bujard (1992). "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters." Proc Natl Acad Sci USA 89(12):5547-5551.; U.S. Patent Nos. 5,888,981, 5,814,618, 6,004,941, 5,814,618, 7,541,446, WO96 / 01313 and WO00 / 75347, all of which are incorporated herein by reference.) It is composed of a tetracycline-dependent regulatory element and a response element containing a TetO operator, and regulates the transcription of a target nucleic acid fragment linked to the response element containing the TetO operator in a tetracycline-inducible manner. The response element containing the TetO operator can bind to a transcription activator under tetracycline-free conditions and initiate the transcription of a downstream controlled target nucleic acid fragment after binding, and can also bind to a tetracycline-dependent repressor under tetracycline-free conditions downstream of a constitutively active promoter and upstream of a controlled target nucleic acid fragment and repress the transcription of the downstream controlled target nucleic acid fragment. Conventionally, a tetracycline-dependent regulatory element binds to the TetO operator under tetracycline-free conditions and dissociates from the TetO operator under tetracycline-containing conditions. For example, activators designed based on this principle can initiate regulated transcription of a target nucleic acid fragment upon removal of tetracycline in the environment (U.S. Patent Nos. 5,464,758, 6,914,124, 5,789,156, 6,271,348, WO96 / 01313 and WO00 / 75347). Subsequently, reverse tetracycline-dependent regulators were developed that bind to the TetO operator only under the condition of tetracycline.Reverse tetracycline-dependent activators can activate the transcription of a controlled target nucleic acid fragment by adding tetracycline to the environment (U.S. Patent Nos. 5,654,168, 6,136,954, 5,789,156, 6,271,348, 6,087,166, 6,271,341, 7,541,446, WO96 / 01313 and WO00 / 75347), for example, by adding tetracycline to the medium to activate the transcription of a controlled target nucleic acid fragment, or by administering tetracycline to a transgenic animal to activate the transcription and expression of a controlled target gene introduced into the body by genetic engineering.

[0004] The transcription activity of the controlled nucleic acid fragment under induction conditions and the leak transcription activity under non-induction conditions are two important indexes for evaluating the superiority or inferiority of an inducible expression system, and a good inducible expression system should have higher inducible transcription activity and lower leak transcription activity. Since the first report, the tetracycline-inducible system has been optimized in many laboratories, and its performance continues to improve. The main optimization involves tetracycline-dependent regulators and response elements containing the TetO operator. The optimization of tetracycline-dependent regulators is mainly focused on: (1) reducing leak transcription activity under non-inducing conditions and increasing the ratio of induced / leaked transcription activity under conditions that maintain the transcription activity after induction as much as possible; (2) optimizing the specificity and affinity of the regulators binding tetracycline and its derivatives as inducers, reaching the maximum induced transcription activity at lower concentrations of tetracycline and its derivatives, and reducing the affinity of the regulators and response elements under conditions without inducers. (See Zhou, X., et al. (2006). "Optimization of the Tet-On system for regulated gene expression through viral evolution." Gene Ther 13(19):1382-1390., U.S. Patent Nos. 8,383,364, 7,541,446.) Optimization of response elements containing TetO operators has mainly focused on the following: (1) optimizing the copy number and linking sequence of TetO operators to improve the performance of response elements and to improve the stability of multi-copy consecutive TetO operator sequences, especially on viral vectors; (2) reducing the uninduced basal leaky transcription activity of a mini promoter under conditions that do not significantly affect transcription activity after induction, and increasing the ratio of induced / leaky transcription activity (See Loew, R., et al. (2010). "Improved Tet-responsive promoters with minimized background expression." BMC Biotechnol 10:81., U.S. Patent No. 9,181,556.).Currently, the commercial tetracycline-inducible system that is widely used is mainly the Tet-On(R) Advanced Inducible Gene Expression Systems (File No.: PT3898-1 (102312) of Clontech Laboratories, Inc., of which the tetracycline-dependent transactivator rtTA and the response element TRE containing the TetO operator (a nucleic acid sequence containing multiple copies of consecutive TetO operator sequences and a minimal promoter sequence, Tet Response Element, hereinafter referred to as TRE) are hereinafter referred to as rtTA, respectively. adv and T.R.E. adv The tetracycline-dependent regulator rtTA and the response element TRE containing the TetO operator are referred to as rtTA, Tet-Off® Advanced Inducible Gene Expression Systems (File No.: PT3945-1(101612)) and Tet-On® 3G Inducible Expression Systems (File No.: PT5148-1(010814)). 3G and T.R.E. 3G (called "the

[0005] The Cumate Inducible System was developed from the p-cym operon of Pseudomonas putida, and consists of a CuO operator downstream of the constitutively active promoter TATA box and a repressor CymR protein that is dependent on Cumate and its derivatives and can bind to the CuO operator. In the absence of Cumate, the CymR protein binds to the CuO operator and represses the transcription of the target nucleic acid fragment controlled downstream, and when the CymR protein binds to Cumate, its affinity with the CuO operator decreases and it is separated, and the transcription of the target nucleic acid fragment controlled downstream is no longer repressed. For example, the CuO operator is linked between the controlled target nucleic acid fragment and the constitutively active promoter sequence, and the CymR repressor is constitutively and actively expressed in cells. In the absence of Cumate and its derivative inducers in the medium, the expressed CymR protein binds to the CuO operator and inhibits the controlled transcription of the target nucleic acid fragment, and when an inducer is added to the medium, the CymR protein bound to Cumate and its derivatives and the CuO operator separate, and the controlled transcription of the target nucleic acid fragment is no longer inhibited (see WO02088346A2, WO2006037215A1 (the above documents are incorporated herein by reference)).

[0006] The optimization of the Cumate induction system is focused on: (1) optimizing the shortest effective CuO operator sequence; (2) screening for water-soluble Cumate and derivative inducers that are functionally similar to p-cumate; (3) constructing a Tet-Off-like induction system consisting of a CymR activator (e.g., a fusion protein that constructs CymR and HSV VP-16 transcription activation domain) and a response element containing multiple copies of consecutive CuO operators (the sequence contains multiple repeated CuO sequences and a downstream minimal promoter). In the absence of Cumate inducer, the CymR activator binds to the CuO operator to activate the transcription of the regulated target nucleic acid fragment, and in the presence of Cumate inducer, the CymR activator dissociates from the CuO operator and the transcription of the regulated target nucleic acid fragment is stopped. (4) We constructed an induction system similar to Tet-On consisting of a reverse CymR activator (through mutation and screening, reverse CymR binds to the CuO operator in the presence of a Cumate inducer and dissociates from the CuO operator in the absence of a Cumate inducer, and constructs a fusion protein of reverse CymR and an HSV VP-16 transcription activation domain to serve as a reverse CymR activator) and a response element containing multiple copies of consecutive CuO operators. In the presence of a Cumate inducer, the reverse CymR activator binds to the response element and activates the transcription of the regulated target nucleic acid fragment, and in the absence of the Cumate inducer, the reverse CymR activator dissociates from the response element and stops the transcription of the regulated target nucleic acid fragment (Mullick, A., et al. (2006). "The cumate gene-switch: a system for regulated expression in mammalian cells." BMC Biotechnol 6:43.; see WO02088346A2, WO2006037215A1). Currently, the widely used Cumate induction system is mainly the SparQ Cumate Switch system (File No.: 1-090810) from SBI System Biosciences.

[0007] In the current development and improvement of various inducible expression systems, the main optimization is focused on controlling the basal leaky transcription activity of the controlled target nucleic acid fragment under non-inducing conditions, and the transcription activity under induced conditions is not the focus of optimization, so the post-induction transcription activity of the target nucleic acid fragment controlled by the inducible expression system is lower than that under the control of a general constitutively active promoter. In the development of biotechnology, improving the absolute post-induction transcription activity of the target nucleic acid fragment is as important as controlling the leaky transcription activity under non-inducing conditions. For example, in the field of biopharmaceuticals, in order to produce a recombinant protein or a viral vector having cytotoxicity, it is necessary not only to increase the post-induction expression level of the protein encoded by the target nucleic acid fragment, but also to control the leaky expression level of the target nucleic acid fragment under non-inducing conditions in order to ensure the culture condition and stability of the production cell line. Therefore, an inducible expression system that can improve the transcription activity of the target nucleic acid fragment under induced conditions and control the leaky transcription activity of the target nucleic acid fragment under non-inducing conditions can widely promote research, development and industrialization in many fields of biotechnology. Summary of the Invention [Problem to be solved by the invention]

[0008] The present disclosure relates to a nucleic acid sequence capable of controlling tetracycline and Cumate-dependent transcription of a target nucleic acid fragment, specifically, the nucleic acid sequence comprises at least two copies of a TetO operator sequence (Tet operator, TetO) that binds to a reverse tetracycline or its derivative-dependent transactivator (rtTA), one copy of a minimal promoter sequence containing a TATA box sequence, and at least one copy of a CuO-operator sequence (Cumate operator, CuO) that binds to a CymR transcription repressor. Furthermore, a splicable intron sequence present downstream of the 3' end of the nucleic acid sequence and upstream of the 5' end of the controlled target nucleic acid fragment can further improve transcriptional activity after induction without leakage without induction. Furthermore, the present disclosure further relates to a vector, virus, cell, transgenic plant or animal that comprises the above control sequence and is intended to control gene expression. [Means for solving the problem]

[0009] The term "target nucleic acid fragment" generally refers to a deoxyribonucleic acid fragment (DNA fragment), and may refer to a nucleic acid sequence encoding a gene, for example, a protein, depending on the application purpose, or may be a part of ribonucleic acid (RNA), for example, a whole or part of a genomic RNA fragment of an RNA virus, microRNA (abbreviated as microRNA, miRNA), small interfering RNA (abbreviated as siRNA), long non-coding ribonucleic acid (abbreviated as lncRNA), guide RNA (gRNA) of the CRISPR gene editing system, transfer ribonucleic acid (abbreviated as transfer RNA, tRNA), ribosomal ribonucleic acid (abbreviated as rRNA), aptamers, a ribonucleic acid fragment capable of binding to other nucleic acids, a ribonucleic acid fragment capable of binding to a specific protein, or any part of a ribonucleic acid, or a combination of a part or a plurality of the above nucleic acid sequences.

[0010] The term "vector" refers to a nucleic acid molecule that is generally used as a vehicle for artificially transporting foreign genetic material, such as the above-mentioned target nucleic acid fragment, to other cells and replicating and / or expressing it therein. Functionally, all vectors can generally be used for cloning and transporting foreign target nucleic acid fragments, while there are also expression vectors that are specifically designed for transcription of nucleic acid fragments and protein expression. Plasmids, viral vectors, cosmids and artificial chromosomes are the four main types of vectors. Here, the most commonly used vector is the plasmid. All engineering plasmid vectors contain an origin of replication that is replicated in bacteria, a multiple cloning site for inserting the target nucleic acid fragment, and a marker gene for selecting positive strains. Viral vectors are another common vector that are usually used to transport genetic material, such as the target nucleic acid fragment, to cells. This process can be carried out in vivo or in cell cultures in vitro. Based on various molecular mechanisms evolved by the virus itself, such as protection of genetic material, selection of host cells based on receptors, delivery of genetic material into host cells, replication and / or expression in host cells, regulation of host cell growth, metabolism, proliferation and replication, and defense mechanisms, inhibition and / or escape from the immune system in higher animals, the virus can effectively transfer the target nucleic acid fragment into the infected target cell. In addition to being used in molecular biology research, viral vectors are also often used in gene therapy, cell therapy, immunotherapy, and vaccine development.

[0011] Usually, an inducible expression system enhances the post-induction transcription activity of the controlled target nucleic acid fragment and increases the leak transcription activity under non-inducing conditions. The general policy of controlling the leak transcription activity under non-inducing conditions, such as the reduction of the affinity of the transactivator with the operator under inducer-free conditions due to point mutation or the reduction of the basal activity of the minimal promoter downstream of the operator, both affect the maximum transcription activity after induction. As a result, most single-inducible expression systems reduce the transcription activation activity of the controlled target nucleic acid fragment under induction conditions to balance the leak transcription activity under non-inducing conditions. Designing a composite inducible expression system containing multiple control components is an effective direction to solve the above problems. In the composite inducible expression system realized by the present disclosure, on the one hand, the maximum transcription activity after induction of the combination of the activator and the corresponding response element in the first inducible expression system is optimized and improved, and on the other hand, the combination of the repressor and the corresponding response element in the second inducible expression system controls the improved leak transcription activity of the composite inducible expression system, for example, the composite inducible expression system uses the Tet-On inducible expression system as the first inducible expression system and the Cumate inducible expression system as the second inducible expression system. The composite response element sequence of the composite inducible expression system includes at least two copies of TetO operator sequence (tet operator) that binds to reverse tetracycline or its derivative controlled transactivator (rtTA), one copy of a minimal promoter sequence containing a TATA box sequence, and at least one copy of CuO operator sequence (CuO operator) that binds to CymR transcription repressor.

[0012] The present inventors have demonstrated that the induced transcriptional activity and the leaky transcriptional activity without induction in the combined inducible expression system of Tet-On and Cumate are affected by three conditions: (1) the multicopy TetO operator and its linked nucleic acid sequence, (2) the minimal promoter sequence in the TRE response element, and (3) the relative positions of the CuO operator and the TATA box in the minimal promoter. 3G The response element is the TRE in the second generation Tet-On system. advIt was found that the closer the CuO operator is to the TATA box, the tighter the control of the leaky transcription activity, but the greater the effect on the induced transcription activity, and the farther the CuO operator is from the TATA box, the weaker the control of the leaky transcription activity, but the smaller the effect on the induced transcription activity. Based on the above findings, the nucleic acid sequence of the present disclosure for controlling the transcription of a target nucleic acid fragment includes at least two copies (e.g., 2, 3, 4, 5, 6, 7 or more copies, preferably 7 copies) of TetO-operator sequence capable of binding to a transactivator rtTA controlled by tetracycline or a derivative thereof, preferably as shown in SEQ ID NO:24, a portion of a minimal promoter sequence including a TATA box sequence, preferably as shown in SEQ ID NO:25 or SEQ ID NO:26, more preferably as shown in SEQ ID NO:25, and a CuO-operator sequence capable of binding to a transcription repressor CymR controlled by cumate, preferably as shown in SEQ ID NO:27. Preferably, at least one CuO operator sequence is downstream of said promoter TATA box, preferably between 10bp and 100bp downstream of the TATA box, for example 14bp, 30bp, 50bp, 100bp, more preferably, only one CuO sequence is between 30bp and 50bp downstream of the TATA box, and more preferably, only one CuO sequence is located at 30bp or 50bp downstream of the TATA box.Preferably, the nucleic acid sequence of the present disclosure for controlling the transcription of a nucleic acid fragment of interest is shown in SEQ ID NO:23, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:30, more preferably, SEQ ID NO:23 or SEQ ID NO:28.

[0013] An intron downstream of a promoter in an expression plasmid can generally improve the stability of messenger RNA (mRNA) transcription, as well as improve the efficiency of mRNA transfer outside the cell nucleus (see Akef, A., et al. (2015). "Splicing promotes the nuclear export of beta-globin mRNA by overcoming nuclear retention elements." RNA 21(11):1908-1920), and can improve the expression level of a target nucleic acid fragment. The present inventors have discovered that linking a splicable intron downstream of the 3' end of a response element in a single induction expression system can also improve the expression level of a controlled target nucleic acid fragment after induction, but can also significantly increase the uninduced leak expression level of the controlled target nucleic acid fragment. Linking a splicable intron sequence downstream of the 3' end of the tetracycline and Cumate-dependent composite response element sequence described in this disclosure and upstream of the 5' end of the controlled target nucleic acid fragment can significantly improve the induced expression level without significantly increasing the uninduced leak expression level. Based on this, in the present disclosure, preferably, a splicable intron fragment is ligated between the downstream of the 3' end of the tetracycline and Cumate-dependent composite response element sequence and the upstream of the 5' end of the target nucleic acid fragment. There is no particular limitation on the selection of the intron, and as can be understood by those skilled in the art, any sequence capable of RNA splicing in mammalian cells can achieve the above function.The intron sequence that can be selected may be any intron in any gene of any eukaryotic organism, including, but not limited to, an intron on a common cloning vector, such as a rabbit β-globulin intron, a hybrid intron derived from a human β-globulin and an immunoglobulin heavy chain intron, EF-1α intron A, an SV40 intron, a hybrid intron derived from an adenovirus and an immunoglobulin heavy chain intron, a modified human cytomegalovirus intron, a hybrid intron derived from a chicken β-actin (CBA) and a mouse mycobacterial virus (MMV) intron, a chimera derived from a chicken β-actin and a rabbit β-globulin intron, and an mP1 intron, or an artificial intron sequence designed based on the intron splicing rules. The intron sequence used in the embodiments of the present disclosure may be that shown in SEQ ID NO:31.

[0014] In the above Tet-On and Cumate combined inducible expression system, in an environment without tetracycline or its derivative and Cumate inducer (Cumate or its functional analogue), the rtTA transactivator cannot bind to the combined response element, and at the same time, the CymR repressor binds to the CuO operator in the combined response element to further inhibit the leak transcription activity of the regulated target nucleic acid fragment due to the non-specific binding of the rtTA transactivator or the basal activity of the minimal promoter; in an environment with only the Cumate inducer, neither the rtTA transactivator nor the CymR repressor bound to the Cumate inducer binds to the combined response element, and the regulated target nucleic acid fragment inhibits the leak transcription activity of the regulated target nucleic acid fragment due to the non-specific binding of the rtTA transactivator or the basal activity of the minimal promoter. Basal activity causes very low amounts of transcription, in the presence of tetracycline or its derivatives only, the rtTA transactivator binds to the TetO operator in the composite response element to activate the transcription of the regulated target nucleic acid fragment, while the CymR repressor simultaneously binds to the CuO operator in the composite response element to allow limited transcription of the regulated target nucleic acid fragment, and in the presence of tetracycline or its derivatives and a Cumate inducer, the rtTA transactivator binds to the TetO operator in the composite response element, while the CymR repressor simultaneously bound to the Cumate inducer dissociates from the CuO operator in the composite response element to allow maximum active transcription of the regulated target nucleic acid fragment. The rtTA transactivator nucleic acid coding sequence is preferably human codon-optimized SEQ ID NO:18, and CymR is preferably human codon-optimized SEQ ID NO:15.

[0015] The above Tet-On and Cumate combined inducible expression system can be applied in any of basic biological science research, biological pharmaceuticals, gene therapy, cell therapy, transgenic plants or animal improvement, including but not limited to controlling the on / off of transcription of protein-coding nucleic acid sequences and controlling the on / off of transcription of non-protein-coding nucleic acid sequences in cells, animals or plants. For example, it may be all or a part of the genomic RNA fragment of an RNA virus, microRNA (abbreviated as microRNA, miRNA), small interfering RNA (abbreviated as siRNA), long non-coding ribonucleic acid (abbreviated as lncRNA), guide RNA (gRNA) of the CRISPR gene editing system, transfer ribonucleic acid (abbreviated as tRNA), ribosomal ribonucleic acid (abbreviated as rRNA), aptamers, ribonucleic acid fragments capable of binding to other nucleic acids, ribonucleic acid fragments capable of binding to specific proteins, or any part of ribonucleic acid, or a combination of a part or a plurality of the above nucleic acid sequences. On the other hand, the above-mentioned Tet-On and Cumate combined inducible expression system can be used for the expression and production of viral vectors in the fields of gene therapy, cell therapy or immunotherapy, for the expression and production of cytotoxic or unstable proteins, for the expression and production of attenuated vaccines or virus-like particle (abbreviated as VLP) vaccines in the vaccine field, and for controlling the on or off of the transcriptional expression of a target nucleic acid fragment in a transgenic animal or plant.

[0016] In the present disclosure, tetracycline and its derivatives that can be used in the Tet-On inducible expression system include compounds structurally similar to tetracycline, which can bind to the tetracycline-dependent transactivator rtTA of the present disclosure, and have a binding constant Ka of at least 10 -6 M, and preferably, its binding constant Ka is 10 -9The tetracycline derivative may be selected from, for example, doxycycline (Dox), anhydrotetracycline (Atc), chlortetracycline, oxytetracycline and deoxytetracycline.

[0017] In the present disclosure, a Cumate functional analogue that binds to the repressor CymR and can be used in the Cumate inducible expression system may be selected from, for example, p-ethylbenzoic acid, p-propylbenzoic acid, p-isopropylbenzoic acid, p-isobutylbenzoic acid, p-tert-butylbenzoic acid, pn-dimethylaminobenzoic acid, pn-ethylaminobenzoic acid, and other Cumate functional analogues described, for example, in U.S. Patent No. 7,745,592.

[0018] The host cell that can be introduced with the vector containing the tetracycline and Cumate co-regulatory sequence of the present disclosure can in principle be any cell, for example, a bacteria, a fungus, an animal cell or a plant cell. On the other hand, the tetracycline and Cumate co-regulatory sequence described in the present disclosure can be used by a viral vector, for example, the nucleic acid fragment contained in the produced viral vector contains the tetracycline and Cumate co-regulatory sequence of the present disclosure, and exists as deoxyribonucleic acid in DNA viral vectors (e.g., adenovirus, adeno-associated virus) and as ribonucleic acid in RNA viral vectors (e.g., retrovirus).

[0019] As can be understood by one skilled in the art, there are no particular limitations on the nucleic acid fragment of interest whose transcription is controlled by the regulatory nucleic acid sequence of the present disclosure, so long as its transcription can be controlled by the regulatory nucleic acid sequence of the present disclosure.

[0020] In one aspect, the present disclosure provides:

[0021] Item 1. A nucleic acid sequence comprising at least two copies of TetO-operator sequences capable of binding to a transactivator rtTA controlled by tetracycline or a derivative thereof, one copy of a minimal promoter sequence containing a TATA box sequence, and at least one copy of CuO-operator sequence capable of binding to a transcriptional repressor CymR controlled by cumate, wherein the CuO-operator sequence is located downstream of the 3' end of the TATA box sequence and is spaced from the TATA box by a distance of 10 bp to 100 bp.

[0022] Item 2. The nucleic acid sequence described in item 1, wherein the distance between the CuO-operator sequence and the TATA box is 30 bp to 50 bp.

[0023] Item 3. The nucleic acid sequence of item 1, wherein the distance between the CuO-operator sequence and the TATA box is 50 bp.

[0024] Clause 4. The nucleic acid sequence of clause 1, wherein the TetO-operator sequence is set forth in SEQ ID NO:24, and / or the minimal promoter sequence is set forth in SEQ ID NO:25 or SEQ ID NO:26, and / or the CuO-operator sequence is set forth in SEQ ID NO:27.

[0025] Item 5. The nucleic acid sequence of item 4, wherein the nucleic acid sequence is set forth in SEQ ID NO:23, SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:30.

[0026] Item 6. The nucleic acid sequence according to any one of items 1 to 5, wherein the nucleic acid sequence further comprises a spliceable intron sequence at the 3' end.

[0027] Item 7. A vector comprising the nucleic acid sequence according to any one of items 1 to 6.

[0028] Item 8. The vector described in Item 7, wherein the vector is an expression vector, the expression vector comprises a target nucleic acid fragment downstream of the 3' end of the nucleic acid sequence described in any one of Items 1 to 6, and the transcription of the target nucleic acid fragment is controlled by the nucleic acid sequence described in any one of Items 1 to 6.

[0029] Item 9. A host cell comprising the nucleic acid sequence according to any one of items 1 to 6 or the vector according to item 7 or 8.

[0030] Section 10. (1) introducing the vector described in paragraph 8, the coding sequence of rtTA and the coding sequence of CymR into a host cell; (2) expressing rtTA and CymR in the host cell that has undergone (1); (3) providing tetracycline or a derivative thereof and cumate or a functional analog thereof to the host cell that has undergone (2).

[0031] Item 11. The rtTA is adv or rtTA 3G 11. The method according to claim 10, wherein

[0032] Item 12. The method according to item 10, wherein the coding sequence of the rtTA is shown in SEQ ID NO.18.

[0033] Item 13. The method according to item 10, wherein the coding sequence of CymR is set forth in SEQ ID NO.15. [Brief description of the drawings]

[0034] [Figure 1]The effect of the position and number of the CuO operator in the composite response element in Example 2 on the induced expression level and the leak expression level without induction of the target nucleic acid fragment is shown. Figure 1A shows the RLU values ​​of the Luciferase detection experiment corresponding to the addition of only DOX inducer and the simultaneous addition of DOX and Cumate inducer. Figure 1B shows the ratio of RLU when Cumate inducer was added and when Cumate inducer was not added. [Diagram 2] The effect of the single regulatory response element, the composite regulatory response element, and the intron linked downstream of the response element in Example 3 on the induced expression level and the leak expression level without induction of the target nucleic acid fragment is shown. Figure 2A: The RLU value of the Luciferase detection experiment corresponding to the presence or absence of DOX and Cumate inducer is shown. Figure 2B: The ratio of RLU values ​​with and without DOX and Cumate inducer is shown. [Diagram 3] Figure 3 shows the effect of different introns in Example 4 on TRE3GCuO composite response element induced expression and leak expression without induction. Figure 3A shows the RLU value of Luciferase detection experiment corresponding to the presence or absence of DOX and Cumate inducer. Figure 3B shows the ratio of RLU value with and without DOX and Cumate inducer. [Figure 4] Figure 1 shows the induced transcription activity of the target nucleic acid fragment under different induction combinations controlled by TRE3GCuO and TRE3GCuO-BGI in Example 5. The ordinate shows the RLU value of the luciferase detection experiment under different induction conditions, the four-color bar graph shows the four combinations with the addition of inducers, and the numbers on the horizontal lines in the middle represent the RLU ratio under the corresponding induction condition and under non-induction condition (white). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] The following examples are provided to illustrate the technical solutions of the present invention, but should not be construed as limiting the scope and spirit of the present invention.

[0036] Example 1: Plasmid construction method

[0037] The molecular cloning techniques used in the following examples, such as PCR amplification of DNA fragments, restriction enzyme digestion of DNA fragments, gel recovery of DNA fragments, T4 DNA ligase ligation of two or more DNA fragments, transformation of ligation products into competent cells, and plasmid minipreparation and identification, are all well known in the art. In the following examples, the following reagents are used: PCR enzyme (Thermo, F-530S), restriction enzyme (NEB), T4 DNA ligase (Invitrogen, 15224041), DNA fragment gel recovery kit (Omega, D2500-02), plasmid extraction mini kit (TIANGEN, DP105-03), competent cells (XL-10 Gold, Hunan Fenghui Bioscience and Technology Co., Ltd., JZ011), and the nucleic acid sequences shown in SEQ ID NO:1 to SEQ ID NO:22 are synthesized by GenScript for constructing the plasmids of the present disclosure, and the sequencing identification is completed by Invitrogen. Table 1 shows primer information for the constructed plasmid, Table 2 shows the composition of elements in the appendix sequence SEQ ID NO:1 to SEQ ID NO:31, Table 3 shows the description of each functional element in the plasmid, and Table 4 shows the plasmid numbers and corresponding names constructed in the present disclosure. The element sequence information adopted in each of the plasmids in the following examples is an example of implementing the present disclosure, and those skilled in the art can expect that the effects described in the present disclosure can be achieved by replacing each element sequence on the plasmid used in the following examples with other element sequences with similar biological functions, including, but not limited to, the backbone sequence of the plasmid (e.g., replication origin, resistance gene, etc.), enzyme cleavage site sequence, transposon repeat sequence, inducible response element sequence, insulator sequence, promoter sequence, intron sequence, polyadenylate signal (PolyA) sequence, gene sequences optimized with different codons, mutants of each of the above functional element sequences and gene sequences, and the cloning positions, cloning order and cloning direction of each functional element sequence and gene sequence. A specific plasmid construction method is as follows:

[0038] 1. Construction of plasmid 18BF007: Plasmid 18BF007 is constructed by digesting the synthetic sequence SEQ ID NO:2 (2900 bp) with NotI and AsiSI and ligating it into the NotI and AsiSI cleavage sites of plasmid 18BF003 (SEQ ID NO:1).

[0039] 2. Construction of plasmid 18BF011: Plasmid 18BF011 is constructed by digesting 18BF007 plasmid with MluI and SphI, gel recovering the 1730 bp fragment and ligating it into the MluI and SphI sites of plasmid 18BF003.

[0040] 3. Construction of plasmid 18BF210: Plasmid 18BF210 is constructed by digesting the synthetic sequence SEQ ID NO:3 (1208 bp) with SpeI and AgeI and ligating it into the AvrII and AgeI sites of plasmid 18BF011.

[0041] 4. Construction of plasmids 18BF211, 18BF212, 18BF213, 18BF214, 18BF215, 18BF216, 18BF217, and 18BF218: The synthetic sequence SEQ ID NO:4 (908 bp), sequence SEQ ID NO:5 (880 bp), sequence SEQ ID NO:6 (890 bp), and sequence SEQ ID NO:7 (845 bp) are cut with MluI and ClaI, respectively, and ligated into the MluI and ClaI cleavage sites of plasmid 18BF210 to construct plasmids 18BF212, 18BF211, 18BF214, and 18BF213, respectively. Plasmids 18BF211, 18BF212, 18BF213 and 18BF214 were each digested with BstBI, and DNA fragments of 3932 bp (18BF211), 3960 bp (18BF212), 3897 bp (18BF213) and 3942 bp (18BF214) were gel-collected and ligated with T4 ligase to construct plasmids 18BF215, 18BF216, 18BF217 and 18BF218, respectively.

[0042] 5. Construction of plasmids 18BF229, 18BF232, 18BF233, 18BF234, 18BF235, 18BF236, 18BF237, 18BF240 and 18BF241: Using pGL3~Basic (Promega, E1751) as a template, plasmids 18BF229, 18BF232, 18BF233, 18BF234, 18BF235, 18BF236, 18BF237, 18BF240 and 18BF241 were cloned using Luc-F (SEQ ID NO: 32) and Luc-R (SEQ ID NO: 33) as a primer. A luciferase gene fragment (1728 bp) was amplified by PCR using primers 18BF229, 18BF232, 18BF233, 18BF234, 18BF235, 18BF236, 18BF237, 18BF240, and 18BF241, respectively, by cleaving the fragment with BamHI and XhoI and ligating the fragment to the BamHI and XhoI cleavage sites of plasmids 18BF210, 18BF217, 18BF218, 18BF215, 18BF216, 18BF211, 18BF212, 18BF213, and 18BF214.

[0043] 6. Construction of plasmids 18BF251, 18BF252, 18BF253, 18BF254, 18BF255, 18BF256 and 18BF257: synthetic sequence SEQ ID NO:8 (414 bp), sequence SEQ ID NO:9 (414 bp), sequence SEQ ID NO:10 (415 bp), sequence SEQ ID NO:11 (472 bp), sequence SEQ ID NO:12 (588 bp), sequence SEQ ID NO:13 (704 bp) and sequence SEQ ID NO:14 (806 bp). Plasmids 18BF251, 18BF252, 18BF253, 18BF254, 18BF255, 18BF256 and 18BF257 are constructed by cutting NO:22 (376 bp) with MluI and ClaI, respectively, and ligating them into the MluI and ClaI cleavage sites of plasmid 18BF235, respectively.

[0044] 7. Construction of plasmids 18BF261, 18BF262, 18BF263 and 18BF264: BGI(C&R) intron sequence (1036bp) was amplified by PCR using SEQ ID NO:17 as template and BGI(C&R)-F (SEQ ID NO:34) and BGI(C&R)-R (SEQ ID NO:35) as primers. Intron(EF-1a) intron sequence (962bp) was amplified by PCR using pEF1alpha-IRES-AcGFP1 (Clontech) as template and Intron(EF-1a)-F (SEQ ID NO:36) and Intron(EF-1a)-R (SEQ ID NO:37) as primers. Intron(pSI)-F (SEQ ID NO:38) and Intron(pSI)-R (SEQ ID NO:39) were amplified by PCR using pSI (Promega#E1721) plasmid as template. Using primer NO:39), amplify the Intron (pSI) intron sequence (152 bp) by PCR, cleave the above three PCR products with ClaI and BamHI, and ligate them to the ClaI and BamHI sites of plasmid 18BF235 to construct plasmids 18BF261, 18BF263, and 18BF264. The synthesized sequence 14 (210 bp) is cleaved with ClaI and BamHI, and ligated to the ClaI and BamHI sites of plasmid 18BF235 to construct plasmid 18BF262.

[0045] 8. Construction of plasmids 19BF075 and 19BF074: The synthetic sequence SEQ ID NO:15 (633 bp) and the sequence SEQ ID NO:16 (1496 bp) are digested with ClaI and XhoI and SpeI and AgeI, respectively, and sequentially ligated into the ClaI and XhoI and AvrII and AgeI cleavage sites of the 18BF007 plasmid to construct the 19BF073 plasmid. The synthetic sequence SEQ ID NO:17 (1979 bp) is digested with MluI and AgeI and ligated into the MluI and AgeI cleavage sites of the 18BF007 plasmid to replace the CMV-BGI-MCS-pA sequence to construct the 18BF008 plasmid. The synthesized sequences SEQ ID NO:18 (768 bp) and SEQ ID NO:19 (765 bp) are digested with ClaI and XhoI, respectively, and ligated into the ClaI and XhoI cleavage sites of the 18BF008 plasmid to construct the 18BF085 and 18BF084 plasmids, respectively. The plasmid 19BF073 is digested with SpeI and AgeI, the 3821 bp fragment is gel-recovered, and ligated into the AvrII and AgeI cleavage sites of the 18BF085 and 18BF084 plasmids, respectively, to construct the 19BF075 and 19BF074 plasmids, respectively.

[0046] 9. Construction of plasmid 18BF019: The synthesized sequence SEQ ID NO:21 (1044 bp) and sequence SEQ ID NO:20 (1320 bp) are cut with BamHI and XhoI and XhoI and BglII, respectively, and ligated into the BamHI and BglII cutting sites of the 18BF011 plasmid to construct the 18BF019 plasmid.

[0047] 10. Construction of plasmids 19BF229, 19BF235, and 19BF237: Plasmids 18BF229, 18BF235, and 18BF237 were digested with MluI and AgeI, respectively, and the 4605 bp (18BF229), 3847 bp (18BF235), and 4341 bp (18BF237) fragments were gel-recovered and ligated into the MluI and AgeI sites of the 18BF007 plasmid to construct plasmids 19BF229, 19BF235, and 19BF237, respectively.

[0048] [Table 1]

[0049] [Table 2] TIFF0007576806000003.tif46170

[0050] [Table 3] TIFF0007576806000005.tif244170 TIFF0007576806000006.tif245170

[0051] [Table 4] TIFF0007576806000008.tif157170

[0052] Example 2: Effect of CuO operator position and number on induced and uninduced leak expression levels

[0053] The experiment described in this example is to study and verify the effect of the position and copy number of the CuO operator in the Tet-On and Cumate composite response elements on the induced expression level of the composite response element and the leak expression level without induction, and to optimize and confirm the optimal CuO operator position and copy number. 3G Based on the 7xTetO sequence in the response element and the minimal promoter sequence #1 (SEQ ID NO: 25), the CuO operator sequence was linked at positions spaced 14 bp, 30 bp, 50 bp, and 100 bp apart downstream of the TATA box, respectively, within a range of 10 bp to 100 bp apart, to construct the TRE. 3G CuO 14 (10-317bp in SEQ ID NO:8), TRE 3G CuO 30 (SEQ ID NO:28), TRE 3G CuO 50 (SEQ ID NO:23) and TRE 3G CuO 100 (10-403bp in SEQ ID NO:10) response elements were designed, and the luciferase reporter gene sequence was linked downstream of the 3' end of the response elements to construct plasmids 18BF251, 18BF252, 18BF235 and 18BF253. In addition, to study the effect of multicopy CuO operator, 2, 4 and 6 copies of CuO operator sequence were inserted at 50bp intervals downstream of the TATA box to generate TREs. 3G CuO 2x (10-411bp in SEQ ID NO:11), TRE 3G CuO 4x (10-527bp in SEQ ID NO:12) and TRE 3G CuO 6x A response element (10-643 bp in SEQ ID NO: 13) was designed, and a luciferase reporter gene sequence was linked to the 3' end downstream of the response element to construct plasmids 18BF254, 18BF255 and 18BF256. 3G and 293T-rtTA, which stably expresses the CymR gene. 3GThe above plasmid was instantly transfected into -CymR cells, and the optimal position and number of the optimized CuO operators were verified by measuring the luciferase fluorescence value of a sample to which DOX and Cumate inducer were added simultaneously, and a control to which only DOX inducer was added. The specific experimental method is as follows:

[0054] 1. 293T-rtTA in the SB transposon system adv -CymR and 293T-rtTA 3G -Construct CymR cells.

[0055] 293T cells were seeded at 1.5E+06 cells per 60 mm dish and cultured in DMEM (Sigma, D6429) complete medium supplemented with 10% FBS (ExCell, 11H116) at 37°C and 5% CO2. After 24 hours of culture, transfection was performed using the PEI method, and 500μL of transfection reagent was added per 60 mm dish at the time of transfection, where the total amount of plasmid was 5.5ug, and the mass ratio of the total amount of plasmid to PEI MAX (Polysciences, 24765-1) was 1:4. Here, transfection was performed with a molar ratio of 10:1 of plasmid 19BF074:18BF019 to produce 293T-rtTA adv -CymR cells were obtained and transfected with plasmids 19BF075:18BF019 at a molar ratio of 10:1 to produce 293T-rtTA 3G -CymR cells were obtained. The plasmid and PEI MAX were mixed homogeneously, left to stand for 15 minutes, and then added to the dish. After 3 hours of transfection, the medium was replaced with DMEM complete medium to complete the transfection procedure. After 24 hours of transfection, the cells were digested with pancreatin and all inoculated into 100 mm dishes (Corning, 430167). After screening with 200 μg / ml hygromycin (Hygromycin, Seiko A600230-0001) drug for at least three generations, the cells were grown with drug pressure and matched with the original 293T cells, and the following experiments were performed.

[0056] 2. Detect the efficacy of each response element under DOX and Cumate induction or DOX only induction conditions based on luciferase fluorescence intensity.

[0057] 293T-rtTA 3G -CymR cells were seeded in a 96-well plate (Corning 3916) at 2.5E+04 cells per well, and the medium was 100 microliters of DMEM complete medium. After 24 hours of culture, 18BF234 (TRE) was added by PEI method. 3G ), 18BF251(TRE 3G CuO 14 ), 18BF252(TRE 3G CuO 30 ), 18BF235(TRE 3G CuO 50 ), 18BF253(TRE 3G CuO 100 ), 18BF254(TRE 3G CuO 2x ), 18BF255(TRE 3G CuO 4x ) and 18BF256(TRE 3G CuO 6x ) plasmid was transfected, and 10μL of transfection reagent was added per well at the time of transfection, where the total amount of plasmid was 0.3ug, including 0.01ug of the above 8 plasmids to be measured and 0.29 micrograms of 18BF003 empty plasmid. The mass ratio of the total amount of plasmid to PEI MAX (Polysciences, 24765-1) was 1:4, and various plasmids were transfected into 6 wells. After 3 hours of transfection, the DMEM complete medium was replaced, and 1ug / ml of DOX (Doxycycline Hydrochloride (DOX) was added to 3 wells, and 200ug / ml of Cumate (Aladdin, I107765) was added to 3 wells, and 1ug / ml of DOX only was added to the other 3 wells. After 24 hours of transfection, the Steady-Glo (R)The relative light units (RLU) of each well were detected using a Luciferase Assay System (Promega, E2610) kit according to its operating instructions (Promega, FB037), and the detector was a fluorescence microplate reader (Perkin Elmer VictorV).

[0058] The results are shown in Figure 1. The CuO operator sequence affects the induced expression level of the Tet-On inducible expression system response element. The closer the CuO operator is to the TRE response element TATA box, the lower the expression level after induction. However, as the distance between the CuO operator and the TATA box increases, the leak expression level without Cumate induction increases. By combining the results of the expression level after induction, the leak expression level without Cumate induction, and the ratio of the Cumate induction / leak expression level, the results were optimal when the distance between CuO and the TATA box was between 30bp and 50bp, and the induced expression levels were 3.06E+06 RLU and 4.53E+06 RLU, respectively, which were the optimal values ​​for TRE response element TATA box and Cumate induction element TATA box. 3G The induced / leak expression ratios based on the Cumate inducible expression system were 44.5% and 66.0%, respectively, of the TRE response element induced expression level. 3G We determined that the CuO operator copies were 4.21 and 2.81 times the TATA box of the TRE response element. Increasing the number of copies of the CuO operator to 2, 4, or 6 further reduced the expression level after induction and did not increase the ratio of Cumate induction / leak expression levels. Based on the above results, the optimal conditions are to insert the CuO operator at a distance of 30 bp to 50 bp away from the TRE response element TATA box and to insert only one copy.

[0059] TRE adv Based on the 7xTetO sequence in the response element and the minimal promoter sequence #2 (SEQ ID NO: 26), the CuO operator sequence was linked to the downstream of the TATA box at positions 32 bp and 52 bp apart, and the TRE was generated by the above-mentioned method. adv CuO 32 (SEQ ID NO:29) and TRE adv CuO 52A response element (SEQ ID NO:30) was designed, and a luciferase reporter gene sequence was linked downstream of the 3' end of the response element to construct plasmids 18BF257 and 18BF233. In the same experimental method as above, the induced expression levels were 3.26+06 RLU and 4.88E+06 RLU, respectively, and the TRE adv The ratios of induced / leak expression levels based on the Cuamte inducible expression system were 37.8% and 53.4%, respectively, of the induced and leaky expression levels of the response element. adv The results showed that the TRE1 response element was 4.97-fold and 3.23-fold higher than that of the TRE1 response element. adv CuO 52 and T.R.E. 3G CuO 50 Experiments were performed with response elements, TRE adv CuO and TRE 3G They were designated as CuO response elements.

[0060] Example 3: Effects of single / combined controls and introns on induced and uninduced leaky expression levels

[0061] In the Tet-On inducible expression system, the TetO operator linking sequence of the TRE response element, the minimal promoter sequence, and different mutants of the transactivator rtTA affect the induced transcription activity and leaky transcription activity in an integrated manner. In addition, by linking a splicable intron sequence downstream of the 3' end of the response element and upstream of the 5' end of the regulated target nucleic acid fragment, it is possible to enhance the transport and stability of messenger ribonucleic acid, but it may also affect the induced transcription activity and leaky transcription activity of the response element in the inducible expression system. Based on this, this embodiment describes (1) TRE adv and T.R.E. 3G Tet-On and Cumate composite response element (TRE) designed based on response element sequences adv CuO and TRE 3G CuO, (2) with or without intron ligation, (3) transactivator rtTA adv or rtTA 3GThe optimal composite response element design plan was confirmed by comparing the ratio of the induced expression level and the induced / leak expression level of the Luciferase gene under three combinations of conditions: control by TRE adv (18BF232), TRE adv CuO(18BF233), TRE 3G (18BF234), TRE 3G CuO(18BF235), TRE adv -BGI(18BF240, response element is TRE adv and a human β-globin intron is linked between the 3' end of the response element and the 5' end of the luciferase gene), TRE adv CuO-BGI (18BF241, response element is TRE adv CuO, in which a human β-globulin intron is linked between the 3' end of the response element and the 5' end of the luciferase gene), TRE 3G -BGI(18BF236, response element is TRE 3G and a human β-globin intron is linked between the 3' end of the response element and the 5' end of the luciferase gene) and TRE 3G CuO-BGI (18BF237, the response element is TRE 3G The positive control was the promoter CMV-BGI (18BF229, the promoter is CMV and the human β-globulin intron is linked between the 3' end of the CMV promoter and the 5' end of the Luciferase gene). adv and 293T-rtTA, which stably expresses the CymR gene. adv -CymR in cells and rtTA 3G and 293T-rtTA, which stably expresses the CymR gene. 3GThe above plasmids were transfected into -CymR cells, and the optimal combination of composite response elements was verified by measuring the luciferase fluorescence values ​​of samples with DOX and Cumate inducers added and the control without induction. The specific experimental method is as follows:

[0062] 293T-rtTA constructed in Example 2 adv -CymR and 293T-rtTA 3G -CymR cells were seeded in a 96-well plate (Corning 3916) at 2.5E+04 cells per well, and the medium was 100 microliters of DMEM complete medium. After 24 hours of culture, the above nine plasmids were transfected by PEI method, and 10 μL of transfection reagent was added per well at the time of transfection, where the total amount of plasmid was 0.3ug, including 0.01ug of the above nine plasmids to be measured and 0.29 micrograms of 18BF003 empty plasmid. The mass ratio of the total amount of plasmid to PEI MAX (Polysciences, 24765-1) was 1:4, and various plasmids were respectively 293T-rtTA adv -CymR and 293T-rtTA 3G -CymR cells were transfected into 6 wells. After 3 hours of transfection, the complete DMEM medium was replaced, and inducers 1ug / ml DOX and 200ug / ml Cumate were added to 3 wells of each type of cell line, while the same amount of medium was added to the other 3 wells as controls. After 24 hours of transfection, Steady-Glo (R) The relative light units (RLU) of each well were detected using a Luciferase Assay System (Promega, E2610) kit according to its operating instructions (Promega, FB037), and the detector was a fluorescence microplate reader (Perkin Elmer VictorV).

[0063] The experimental results are shown in Figure 2. (1) The TRECuO composite response element significantly improved the ratio of induced / leak expression by 1 to 2 orders of magnitude compared with the TRE single control response element. 3G The CuO complex response element is TRE adv The CuO complex response element can better control leak expression. 293T-rtTA adv In -CymR cells, TRE 3G CuO and TRE adv The induction / leak expression ratios of CuO were 1565 and 1345 times, respectively, which was improved by 16.4%, and 293T-rtTA 3G In -CymR cells, TRE 3G CuO and TRE adv The induction / leak expression ratios of CuO were 2635 and 1915 times, respectively, which was an improvement of 37.6%. However, the induction expression level of the TRECuO composite response element was significantly lower than that of the TRE single control response element. adv In -CymR cells, TRE 3G CuO and TRE adv The induced expression level of CuO was 3G and T.R.E. adv The single regulatory response elements accounted for 50.4% and 36.3%, respectively, of the 293T-rtTA 3G In -CymR cells, TRE 3G CuO and TRE adv The induced expression levels of CuO were 61.8% and 40.3%, respectively, of the single regulatory response elements. (2) In terms of induced expression levels, TRE 3G The CuO complex response element is TRE adv The CuO complex response element was more sensitive to downstream introns, and the intron BGI design significantly improved the inducible expression level. 3G CuO and TRE 3G The induced expression level of CuO-BGI was 293T-rtTA adv In -CymR cells, the RLUs were 3.4E+06 and 10.6E+06, respectively, which were 3GThe induced expression levels of the TRE gene were 50.4% and 157.9%, respectively, by linking the intron. 3G After induction, the expression level of the CuO complex response element was increased by 2.13-fold, and the 293T-rtTA 3G In -CymR cells, the values ​​were 4.24E+06 and 11.3E+06, respectively, which were 3G The induced expression levels of the TRE1 gene were 61.8% and 165.0%, respectively, and the intron was ligated to the TRE1 gene. 3G The expression level of the CuO complex response element after induction was increased by 1.67 times. (3) The expression level of the transactivator rtTA 3G In eight design proposals, rtTA adv There was no significant difference between the induced and leaky expression levels of rtTA. 3G The average induction / leakage ratio of the eight designs was 1110-fold higher than that of rtTA. adv 1.68 times (rtTA adv The average induction / leak expression ratio was 661-fold.

[0064] Based on the above results, TRE 3G The CuO complex response element is TRE adv and T.R.E. 3G and TRE adv The CuO complex response element has the ability to better control leak expression and is involved in the downstream intron BGI and TRE 3G The control of leak expression by the CuO complex response element can be maintained, and the amount of induced expression can be significantly increased. 3G Under controlled conditions, TRE 3G The induced expression levels of CuO-BGI were adv 80.6% of TRE adv - 80.5% of BGI and TRE adv CuO 199.9%, TRE adv CuO-BGI is 147.0% and TRE 3G This is 165.0% of TRE 3G - 81.5% of BGI and TRE 3GCuO was 267.2%, while the constitutively active promoter CMV-BGI reached 84.7%, and TRE 3G The ratio of induced / uninduced expression of CuO-BGI was calculated by TRE adv 24.5 times TRE adv - 43.4 times BGI, TRE adv 1.2 times that of CuO, TRE adv 1.6 times that of CuO-BGI, TRE 3G 5.9 times, TRE 3G - 8.9 times BGI and TRE 3G It is 0.8 times that of CuO.

[0065] Example 4: TRE 3G Effects of different introns on induced and uninduced leaky expression of the CuO complex response element

[0066] In the above Example 3, the intron BGI was ligated to 3G The CuO complex induction response element significantly improved the inducible transcription activity and expression of the Luciferase target gene. This example examined whether other introns had similar effects. This example examined whether introns on four common plasmid vectors could be used as TREs. 3G The 3' end of the CuO complex response element was cloned downstream and the 5' end of the luciferase reporter gene was cloned upstream to construct plasmids 18BF261, 18BF262, 18BF263 and 18BF264, which contain BGI(C&R), Intron(mP1), Intron(EF-1a) and Intron(pSI), respectively. The specific method of constructing the plasmids is described in Example 1. 3G and 293T-rtTA, which stably expresses the CymR gene. 3G -CymR cells, the above plasmid and TRE 3G CuO(18BF235), TRE 3GThe CuO-BGI (18BF237) and CMV-BGI (18BF229) plasmids were instantly transfected, and the luciferase fluorescence values ​​of the samples with and without DOX and Cumate inducers were measured. 3G The effect of each intron on the induced expression and the leaky expression of the CuO complex response element without induction was examined. The specific experimental method is as follows:

[0067] 293T-rtTA 3G -CymR cells were seeded in a 96-well plate (Corning 3916) at 2.5E+04 cells per well, and the medium was 100 microliters of DMEM complete medium. After 24 hours of culture, the above seven plasmids were transfected respectively by PEI method, and 10 μL of transfection reagent was added per well at the time of transfection, where the total amount of plasmid was 0.3ug, including 0.01ug of the above seven plasmids to be measured and 0.29 micrograms of 18BF003 empty plasmid. The mass ratio of the total amount of plasmid to PEI MAX (Polysciences, 24765-1) was 1:4, and various plasmids were transfected into 6 wells. After 3 hours of transfection, the DMEM complete medium was replaced, and the inducer 1ug / ml DOX and 200ug / ml Cumate were added into 3 wells, and the same amount of medium was added into the other 3 wells. After 24 hours of transfection, Steady-Glo (R) The relative light units (RLU) of each well were detected using a Luciferase Assay System (Promega, E2610) kit according to its operating instructions (Promega, FB037), and the detector was a fluorescence microplate reader (Perkin Elmer VictorV).

[0068] The experimental results are shown in Figure 3. The four other intron-containing plasmids 18BF261, 18BF262, 18BF263 and 18BF264 showed significantly higher TRE expression levels and induced / leak expression levels. 3GThere was no significant difference from CuO-BGI (18BF237), and both were TREs described in Example 3. 3G The designed effect of CuO-BGI can be achieved. Introns require a 5' splice site, a 3' splice site, and a splicing branch point to perform splicing. This example proves that any splicable intron that meets the above conditions can achieve the experimental effect described in this disclosure. Therefore, the effect described in this disclosure should not be restricted by a specific intron sequence, and any sequence that can perform RNA splicing in mammalian cells can achieve the above function. The intron sequence that can be selected includes, but is not limited to, introns on common cloning vectors, such as rabbit β-globulin intron, hybrid introns derived from human β-globulin and immunoglobulin heavy chain introns, EF-1α intron A, SV40 intron, hybrid introns derived from adenovirus and immunoglobulin heavy chain introns, modified human cytomegalovirus introns, hybrid introns derived from chicken β-actin (CBA) and mouse mycobacterial virus (MMV) introns, chimeras derived from chicken β-actin and rabbit β-globulin introns, and mP1 introns, but may also be any intron of any gene of any eukaryote, or an artificial intron sequence designed based on intron splicing rules.

[0069] Example 5: TRE 3G The inducible transcriptional activity of CuO complex response elements under different induction combinations is studied.

[0070] This example shows the TRE regulated by the Tet-ON and Cumate complex. 3G CuO or TRE 3GStable cell lines designed based on the CuO-intron and using Luciferase as a reporter gene were constructed, and based on these cell lines, the different induced transcriptional activities of the reporter gene were detected under four combinations of induction conditions: no inducer, addition of Cumate only, addition of DOX only, or simultaneous addition of DOX and Cumate inducer. In this example, only the Luciferase reporter gene is used as an example, and in principle, the method described in this disclosure is not affected by the target nucleic acid fragment. The specific experimental method is as follows:

[0071] 1.Constructing DOX and Cumate combined regulated Luciferase stabilized cell line using SB transposon system:

[0072] 293T cells were seeded at 1.5E+06 cells per 60mm dish and cultured in DMEM (Sigma, D6429) complete medium supplemented with 10% FBS (ExCell, 11H116) at 37℃, 5% CO2. After 24 hours of culture, they were transfected by PEI method. At the time of transfection, 500μL of transfection reagent was added per 60mm dish, the total amount of plasmid was 5.5ug, and the mass ratio of the total amount of plasmid to PEI MAX (Polysciences, 24765-1) was 1:4. A total of three Luciferase-stabilized cell lines were constructed. Here, plasmid transfection was performed at a molar ratio of 19BF075:19BF229:18BF019 (5:5:1) to obtain 293T(T&C)-CMV-BGI-Luc cells, and here, plasmid transfection was performed at a molar ratio of 19BF075:19BF235:18BF019 (5:5:1) to obtain 293T(T&C)-TRE 3G CuO-Luc cells were obtained, in which plasmid transfection was performed at a molar ratio of 5:5:1, 19BF075:19BF237:18BF019, to 293T(T&C)-TRE. 3GCuO-BGI-Luc cells were obtained. The plasmid and PEI MAX were mixed homogeneously, left for 15 minutes, and then added to the dish. After 3 hours of transfection, the medium was replaced with DMEM complete medium to complete the transfection procedure. After 24 hours of transfection, the cells were digested with pancreatin and all were inoculated into 100 mm dishes (Corning, 430167) and screened with 200 μg / ml hygromycin (A600230-0001) drug for at least three generations. After the cells were grown under the pressure of the drug to match the original 293T cells, the above three cells were further diluted to one cell per well by limiting dilution method and inoculated into a 96-well plate. When the cells grew to about 50% of the bottom area of ​​the well, the wells with strong green fluorescence intensity of EGFP and uniform emission were selected under a fluorescent microscope, and three independent clones of each type of cell were selected for the following experiments.

[0073] 2. Induce Luciferase expression by different combinations of DOX and Cumate:

[0074] Three independent clones of each of the above three cells were seeded into 96-well plates (Corning 3916) at 2.5E+04 cells per well, with each clone seeding 8 wells, and the medium was 100 microliters of DMEM complete medium. After 24 hours of culture, the medium was replaced and duplicate wells were taken within the 8 culture wells of each cell clone, and (1) an equal volume of medium, (2) Cumate at a final concentration of 200ug / ml, (3) DOX at a final concentration of 1ug / ml, or (4) DOX at a final concentration of 1ug / ml and Cumate at 200ug / ml, respectively. After another 24 hours of culture, the cells were incubated with Steady-Glo (R) The relative light units (RLU) of each well were detected using a Luciferase Assay System (Promega, E2610) kit according to its operating instructions (Promega, FB037), and the detector was a fluorescence microplate reader (Perkin Elmer VictorV).

[0075] The experimental results are shown in Figure 4. Under the condition where only Cumate was added, TRE 3G CuO and TRE 3G The induced transcriptional activity of CuO-BGI was 1.36E+04 RLU and 4.16E+04 RLU, which were 4.31-fold and 3.27-fold higher than those of the non-induced condition, respectively. 3G CuO and TRE 3G The induced transcriptional activity of CuO-BGI was 2.14E+05 RLU and 5.34E+05 RLU, which was 67.66-fold and 42.07-fold higher than the non-induced condition and 15.71-fold and 12.86-fold higher than the induced condition with only Cumate added. 3G CuO and TRE 3G The induced transcription activity of CuO-BGI was 7.54E+06 RLU and 1.29E+07 RLU, which was 2381.05-fold and 1011.81-fold higher than the non-induced condition, 552.99-fold and 309.27-fold higher than the induced condition with Cumate alone, and 35.19-fold and 24.05-fold higher than the induced condition with DOX alone. Based on the above results, TRE 3G CuO and TRE 3G The CuO-BGI composite response element can control the induced transcription activity of the target nucleic acid fragment at different transcription activity levels according to different inducer control combinations, and the control ranges are 4.31-fold to 2381.05-fold and 3.27-fold to 1011.81-fold, respectively. When DOX and Cumate inducers are added simultaneously, the maximum induced transcription activity can reach 47.84% and 81.54% of the CMV promoter, respectively. Furthermore, under the conditions of optimizing the concentration of DOX and / or Cumate inducer, the transcription activity of the target nucleic acid fragment can be precisely controlled at different transcription activity levels.

Claims

1. A nucleic acid molecule comprising, in that order, at least two copies of TetO-operator sequences capable of binding to a tetracycline-controlled transactivator rtTA, one copy of a minimal promoter sequence containing a TATA box sequence, and at least one copy of CuO-operator sequence capable of binding to a cumate-controlled transcriptional repressor CymR, wherein the CuO-operator sequence is downstream of the 3' end of the TATA box sequence and is 30 bp to 50 bp away from the TATA box.

2. The nucleic acid molecule of claim 1, wherein the distance between the CuO-operator sequence and the TATA box is 50 bp.

3. 2. The nucleic acid molecule of claim 1, wherein the TetO-operator sequence is shown in SEQ ID NO: 24, and / or the minimal promoter sequence is shown in SEQ ID NO: 25 or SEQ ID NO: 26, and / or the CuO-operator sequence is shown in SEQ ID NO:

27.

4. The nucleic acid molecule of claim 3 , wherein the sequence of the nucleic acid molecule is set forth in SEQ ID NO: 23, SEQ ID NO: 28, SEQ ID NO: 29 or SEQ ID NO:

30.

5. The nucleic acid molecule according to any one of claims 1 to 4, further comprising a spliceable intron sequence at the 3' end.

6. A vector comprising the nucleic acid molecule according to any one of claims 1 to 5.

7. The vector according to claim 6, wherein the vector is an expression vector, the expression vector comprises a target nucleic acid fragment downstream of the 3' end of the nucleic acid molecule according to any one of claims 1 to 5, and the transcription of the target nucleic acid fragment is controlled by the nucleic acid molecule according to any one of claims 1 to 5.

8. A host cell comprising a nucleic acid molecule according to any one of claims 1 to 5 or a vector according to claim 6 or 7.

9. (1) introducing the vector of claim 7, the coding sequence of rtTA and the coding sequence of CymR into a host cell; (2) expressing rtTA and CymR in the host cell that has undergone (1); (3) providing tetracycline or a derivative thereof and cumate or a functional analog thereof to the host cell that has been subjected to (2); Including, wherein the derivative is selected from the group consisting of doxycycline, anhydrotetracycline, chlortetracycline, oxytetracycline and deoxytetracycline, and The functional analogue is selected from the group consisting of p-ethylbenzoic acid, p-propylbenzoic acid, p-isopropylbenzoic acid, p-isobutylbenzoic acid, p-tert-butylbenzoic acid, p-n-dimethylaminobenzoic acid and p-n-ethylaminobenzoic acid; A method for inducing expression of a nucleic acid fragment of interest in said host cell.

10. The rtTA is adv or rtTA 3G The method according to claim 9, wherein

11. 10. The method of claim 9, wherein the coding sequence of the rtTA is shown in SEQ ID NO.

18.

12. 10. The method of claim 9, wherein the coding sequence of CymR is set forth in SEQ ID NO. 15.

Citation Information

Patent Citations

  • A system for inducible expression in eukaryotic cells

    WO2002088346A2